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Case presentation
A 56-year-old black woman was admitted to the Hospital of the
University of Pennsylvania for reevaluation of diffuse bone pain and
muscle weakness. She had been in good health until 5 years prior to
admission, when she developed a diffuse aching pain in her chest and
extremities. Three years before admission, she complained of increas-
ing muscle weakness, worsening hip pain, and thoracic pain and
discomfort accentuated by respiration. Family history was negative for
bone or renal disease.
Laboratory evaluation revealed normal BUN, creatinine, uric acid,
and serum electrolyte levels, an elevated alkaline phosphatase of 750
IU, serum calcium ranging between 9.0 and 9.4 mg/dI, and serum
phosphate between 1.0 and 1.8 mg/dl. Total protein was 7.8 g/dl, with a
serum albumin of 3.5 g/dl. Urine pH ranged between 5.0 and 5.5, and a
urine screen for amino acids was normal except for increased 24-hr
excretion of hydroxyproline. Serum PTH was normal, and plasma
l,25(OH)2D3 was 56 pmollliter (normal, 89 25). A 24-hour urine
collection contained 1150mg of creatinine, 179mg of calcium, and 540
mg of phosphate, at a time when serum phosphate was 1.3 mgldl and the
serum creatinine was 1.0 mg/dl; the fractional phosphate excretion was
33%. A bone survey revealed extensive demineralization, multiple rib
fractures, and fractures of the right superior and left inferior pubic rami
without callus formation. The urine was negative for Bence Jones
protein. Biopsy of the posterior iliac crest revealed osteomalacia. A 72-
hour stool fat collection revealed less than 1.5 g/day, and a jejunal
biopsy was normal. Intravenous pyelogram, an upper and lower gas-
tointestinal series, liver scan, bone marrow aspiration, and mammogra-
phy all were normal.
The patient was treated over the next several years with various
combinations of oral phosphate, calcium, and vitamin D. On a regimen
of 2.5 g/day of elemental phosphorus, 2 glday of calcium carbonate, and
50,000 units of vitamin D every other day, the serum phosphate ranged
between 2.2 and 2.8 mgldl, and the serum calcium fluctuated between
9.5 and 10.5 mg/dl. She continued to complain of diffuse bone pain and
muscle weakness and subsequently was treated with I rg/day of I aOH
vitamin D and 3 g/day of elemental phosphorus. On this regimen, the
serum phosphate varied between 1.8 and 2.1 mg/dl, the serum calcium
level ranged between 8.2 and 8.6 mg/dl, and the PTH increased from 9
to 12 tlEq/ml. Treatment with calcium carbonate was reinstituted, but
after 6 months of therapy the patient was readmitted for evaluation
because of continuing bone pain.
On admission, she complained of new discomfort and pressure in the
left plantar area. The blood pressure was 140/86 mm Hg; pulse, 72; and
weight, 186 lbs. Funduscopic examination showed minimal arteriolar
narrowing, sharp discs, and no hemorrhages or exudates. The rib cage
was diffusely tender to palpation. Examination of the heart and lungs
was normal. Neither hepatosplenomegaly nor costovertebral angle
tenderness was present. There was a firm, slightly tender, small nodule
barely palpable in the sole of the left foot.
The BUN was 12 mg/dl and the serum creatinine was 1.1 mg/dl.
Blood chemistry studies revealed: sodium, 136 mEq/liter; potassium,
3.6, mEq/liter; chloride, 104 mEq/liter; and bicarbonate, 27 mEq/liter.
Serum calcium was 9.5 mg/dl, and phosphate was 2.3 mg/dl, with a
fractional phosphate excretion of 58%. Serum protein was 7.6 g/dl;
serum albumin was 3.8 gIdl. Urinalysis showed a pH of 5.0; a specific
gravity of 1.014; and no protein, glucose, cells, or casts. Alkaline
phosphatase was 620 lU/liter; serum I ,25(OH)2D3, Ill pmol/liter; and
PTH, 7 bdEq/ml.
Chest x-ray revealed multiple rib fractures. The heart was normal in
size and the lung fields were clear. A blood-pool study of the left leg
with Tc-labeled albumin revealed a vascular tumor of the left foot, and
left femoral arteriography demonstrated an extensive lesion in the
region of the proximal metatarsal bones with involvement of the skin of
the proximal half of the foot.
Biopsy of the involved area revealed a sclerosing hemangioma; a
below-the-knee amputation was performed. Following surgery, the
serum phosphate level rose within 48 hours to 4.1 mg/dl, and the
fractional phosphate excretion fell to 16%. Six months later the patient
was well and had no bone pain; x-ray films of the pelvis revealed almost
complete healing of the fractures of the pubic rami. Four years later,
serum calcium was 9.3 mg/dl; serum phosphate, 4.8 mg/dl; and alkaline
phosphatase, 87 lU/liter.
Discussion
DR. ZALMAN S. AGUS (Associate Professor of Medicine,
University of Pennsylvania School of Medicine, and Chief,
Renal-Electrolyte Section, Hospital of the University of Penn-
sylvania, Philadelphia, Pennsylvania): This patient, previously
in good health, experienced at age 48 marked hypophosphate-
mia, low levels of I ,25(OH)2D3, renal phosphate wasting, and
symptomatic bone disease in the presence of normocalcemia
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Fig. 1. Sites of phosphate transport along the mammalian nephron in
the absence of PTH. (© 1983, the Williams & Wilkins Co., Baltimore, in
prep.)
and normal levels of PTH. Large doses of phosphate and
supraphysiologic doses of la-vitamin D did not alleviate her
disease, but the removal of a scierosing hemangioma immedi-
ately resolved all symptoms. The patient thus illustrates ac-
quired vitamin D-resistant rickets due to tumor-induced or so-
called oncogenic osteomalacia. Before discussing the pathogen-
esis and therapy of vitamin D-resistant rickets, I would like to
review some of the current concepts concerning the interrela-
tionship between renal phosphate transport and vitamin D
metabolism.
Renal phosphate transport
Sites of transport. Our knowledge of the sites of phosphate
transport within the nephron, the factors that alter transport,
and the mechanisms by which transport takes place has been
expanded considerably in the last decade by data obtained by
micropuncture, isolated nephron segment perfusion studies,
and studies of membrane vesicles [1, 2]. Phosphate transport
occurs throughout the nephron, except in the loop of Henle.
Figure 1 represents a composite view of transport sites in the
mammalian nephron in the absence of increased levels of
parathyroid hormone [3]. Phosphate is transported in all seg-
ments of the proximal tubule, but the rate of transport per unit
length seems to diminish along the tubule and is higher in the
convoluted segment than in the straight segment. Because
juxtamedullary nephrons have a longer convoluted segment
than do superficial nephrons, fractional reabsorption of the
filtered phosphate load is higher, and therefore fractional deliv-
ery into the thin descending limb of Henle's loop is less in
deeper than in superficial nephrons, No net phosphate transport
occurs in the thin descending, thin ascending, and thick ascend-
Table 1. Factors that alter urinary
phosphate excretion
Plasma phosphate concentration
Dietary phosphate intake
Proximal tubular sodium reabsorption
Extracellular fluid volume
Acetazolamide
Hormones
Parathyroid hormone
Growth hormone
Thyrocalcitonin
Insulin
1,25(OH)2D3 (?)
Acid-base balance
Plasma glucose concentration
Serum calcium concentration
ing limbs of Henle's loop. A small fraction of the filtered load is
reabsorbed in the distal convoluted tubule, and a much smaller
component is reabsorbed in the cortical collecting tubule and
medullary collecting duct. Transport beyond the distal tubule is
not altered by the factors that normally regulate phosphate
homeostasis, and transport here is driven by purely passive
forces such as voltage, tubular flow, and concentration
gradients.
Factors altering phosphate transport. Table I lists some of
the many factors that alter renal phosphate transport and
excretion [1]. Studies in experimental animals have shown that
increases in PCO2, filtered glucose load, and hypercalcemia
diminish tubular phosphate transport and increase phosphate
excretion, whereas hyperinsulinemia and chronic administra-
tion of growth hormone stimulate phosphate transport [I]. The
role of vitamin D and its metabolites remains controversial and
will be discussed subsequently. In terms of day-to-day homeo-
static regulation of phosphate balance, however, two factors
are most important: plasma levels of circulating PTH and
dietary phosphate intake.
Parathyroid hormone, via stimulation of adenylate cyclase
activity, inhibits transport in the proximal convoluted tubule,
pars recta, and distal convoluted tubule. In the presence of
normal plasma levels of PTH, distal phosphate transport is
inhibited, and the bulk of renal phosphate transport occurs
within the proximal tubule. In the absence of parathyroid
hormone, transport capacity is increased in both segments and
leads to an increased transport maximum (Tm) for phosphate,
and thus hyperphosphatemia.
In recent years, it has become clear that dietary phosphate
intake is a powerful regulator of phosphate excretion. Studies in
humans and experimental animals show a significant fall in
phosphate excretion within the first 24 hours of phosphate
deprivation, and virtual elimination of phosphate from the urine
within 72 hours [4, 5]. As shown in Figure 2, this renal
adaptation limits, but does not prevent, phosphate depletion
following dietary phosphate deprivation because of continued
gastrointestinal phosphate secretion and phosphate loss in the
stool [4]. Although not well understood, the mechanism of this
adaptation is not a function of the fall in serum phosphate or of a
reduction in PTH secretion. Thus although both of these events
occur and may contribute to the fall in phosphate excretion,
other unknown factors seem to be more important. In fact, in
the animal adapted to phosphate deprivation, neither acute
Final Urine: 1-3%
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elevation of the filtered load nor infusion of PTH produces a
significant change in phosphate excretion [6, 7].
Cellular mechanisms of transport. The study of vesicles
prepared from renal brush-border membranes has generated
new concepts of phosphate transport [2]. Figure 3 illustrates a
current working model for phosphate transport. Vesicle studies
indicate that an active sodium-dependent phosphate uptake
mechanism is present at the brush border [8, 9]. This cotrans-
port process, which occurs against an electrochemical gradient
for phosphate, is secondarily active, in effect being fueled by
the energy utilized in maintaining the transmembrane sodium
gradient, which allows inward diffusion of sodium and phos-
phate. Direct measurements are lacking, but using measure-
ments in other tissues, researchers have assumed that the
intracellular inorganic phosphate concentration approximates
that in the extracellular fluid. In combination with a favorable
electrical gradient, this concentration allows for passive exit of
phosphate at the contraluminal membrane, Consistent with this
hypothesis is the demonstration that phosphate transport across
the basolateral membrane of the renal tubular cell is sodium
independent [91.
This model allows for modulation of net phosphate transport
in several ways. First, phosphate transport can be inhibited
indirectly by reducing the rate of diffusion of sodium into the
cell. Thus, inhibition of sodium-potassium ATPase leads to an
increase in intracellular sodium concentration and a reduced
gradient for sodium entry. Second, phosphate transport can be
modified directly and specifically in the presence of a constant
sodium gradient by alteration of either the affinity of the brush-
border membrane for phosphate or the Vmax or capacity of the
uptake system itself. Under most conditions, the capacity of the
brush-border system seems to be the rate-limiting step in renal
phosphate transport. Favoring this concept is the demonstra-
tion that most factors that alter net proximal reabsorption of
phosphate in vivo similarly alter net phosphate uptake by
brush-border membrane vesicles prepared from treated animals
[2]. In addition, a decrease in sodium-dependent phosphate
transport is observed in vesicles isolated from animals acutely
given PTH and cyclic AMP [10] and in animals chronically
given l,25(OH)2D3 [11]; increases in uptake have been ob-
served repeatedly in vesicles prepared from animals treated
with a low-phosphate diet [2].
The mechanism by which modifiers of phosphate transport
alter brush-border uptake is an area of intense investigation.
Although initial studies suggested a correlation with membrane-
bound alkaline phosphatase activity, more recent studies have
dissociated enzyme activity and phosphate transport [12]. Nico-
tinamide administration in vivo but not in vitro leads to phos-
phaturia, specific inhibition of sodium-dependent brush-border
membrane phosphate uptake, and increased renal cortical NAD
levels [13]. Because NAD added to vesicles also inhibits brush-
border uptake, it has been suggested that cytoplasmic NAD
levels, by interacting with membrane protein, could serve as a
physiologic control of phosphate transport. Circumstantial evi-
dence marshaled for this hypothesis includes the demonstration
that phosphaturic factors such as PTH, cAMP, glucocorticoid
administration, and metabolic acidosis stimulate gluconeogene-
sis, and thereby NAD levels [13]. Additionally or alternatively,
cAMP may directly alter a membrane transport protein by
protein kinase-mediated phosphorylation. In accord with this
hypothesis, recent studies demonstrated cAMP-dependent
phosphorylation of 2 protein bands (MW = 96,000 and 62,000)
in brush-border membrane vesicles in vitro, and this phosphor-
ylation was associated with a significant decrease in sodium-
dependent phosphate, but not D-glucose, transport [14].
Relationship between phosphate transport and vitamin D
metabolism. As stated, the effect of vitamin D on phosphate
transport remains controversial. Although recent studies clear-
ly demonstrate increased intestinal phosphate absorption with
l,25(OH)2D3 administration [15], experimental data relating to
effects on the kidney are variable and conflicting [16]. It has not
been possible to demonstrate effects of D metabolites on
phosphate transport in normal subjects when parathyroid hor-
mone is controlled, but changes can be observed in selected
conditions. Parenteral administration of l,25(OH)2D3 to ani-
mals receiving vasopressin or PTH, that is, animals with
increased basal intrarenal cAMP levels, reduces phosphate
excretion acutely [17, 18]. Also, 25(OH)D3 reduces urinary
cAMP excretion [18]. In sharp contrast to these acute changes,
chronic treatment of parathyroidectoniized animals with
l,25(OH)2D3 reduces the elevated Tm for phosphate and in-
creases phosphate excretion [19]. Recent studies in isolated
cells corroborate both of these seemingly discrepant observa-
tions [20]. Liang and coworkers found that administration of
1 ,25(OH)2D3 to vitamin D-deficient chicks was associated with
increased phosphate uptake by isolated renal tubular cells when
studied 3 hours later; 17 hours later, however, phosphate
uptake was reduced. In both these studies and those involving
chronic administration of vitamin D to thyroparathyroidecto-
mized animals, the serum phosphate level had increased by the
time phosphaturia occurred in vivo or when decreased cellular
uptake was observed in vitro. It is therefore possible that acute
administration of 1 ,25(OH)2D3 stimulates phosphate uptake,
but that chronic administration represents a more complex
situation in which changes in filtered load and cellular phos-
phate concentration produce different effects. The relationship
of these observations to homeostatic regulation of phosphate
and disordered states of phosphate homeostasis remains un-
clear, however. As I will discuss subsequently, the relationship
between tubular phosphate transport and vitamin D metabolism
in vitamin D-resistant rickets is an area of intense interest. In
addition to the putative effects of vitamin D metabolites on
phosphate transport, it is clear that phosphate is an important
regulator of 25(OH)D3-la hydroxylase activity. Thus in humans
and experimental animals, phosphate deprivation is a potent
stimulus to l,25(OH)2D3 production, as is parathyroid hormone
[4, 21, 22]. Another intriguing relationship between phosphate
transport and 1 ,25(OH)2D3 is the localization of the site of
l,25(OH)2D3 and 24,25(OH)2D3 production to the proximal
tubule, the major site of phosphate transport [23, 24].
Differential diagnosis of chronic hypophosphatemia
Hypophosphatemia can reflect a negative phosphate balance
and body deficits of phosphate. It also can be produced acutely
if the cellular uptake of phosphate is increased at the expense of
the extracellular fluid concentration. The latter instance, which
occurs with acute disturbances such as respiratory alkalosis and
insulin administration, or with hyperalimentation, has been
discussed previously in this forum by Eberhard Ritz [25].
Because phosphate is absorbed from the gastrointestinal tract
Fig. 2. Urina,y and fecal phosphate excretion in
man in response to phosphate deprivation.
(Adapted from Ref. 2.)
Interstitial
Fluid Cell Interior Tubular Lumen
OmY 65mV
1.6 mM mM Pi
and undergoes renal excretion, negative phosphate balance
reflects a disturbance in one or both of these organ systems.
Under normal conditions, approximately 60% to 70% of dietary
phosphorus is absorbed from the gastrointestinal tract, princi-
pally in the small bowel. At the same time, approximately 200
mg of phosphate per day is secreted into the stool. Gastrointes-
tinal phosphate absorption can be increased by the administra-
tion of vitamin D metabolites, but there seems to be little
modulation or control of gastrointestinal secretion. Thus, al-
though the kidney adapts quickly to dietary phosphate depriva-
tion, continued loss of phosphate into the stool over a pro-
longed period can produce negative phosphate balance and
hypophosphatemia [4]. A more severe negative phosphate
balance due to increased phosphate loss in the stool occurs with
antacid administration because antacids bind phosphate in the
intestinal lumen. Thus, clinical situations exist in which signifi-
cant chronic hypophosphatemia can be a manifestation of
gastrointestinal phosphate loss. This entity can be suspected
from the patient's medical history and can be documented by an
evaluation of the urinary phosphate excretion. As we have
seen, the renal adaptation to decreased phosphate intake is
characterized by virtual elimination of phosphate from the
urine. The presence of significant amounts of phosphate in the
urine, that is, more than 100 mg per 24 hours, in the presence of
severe hypophosphatemia (less than 2 mg/dl) indicates that the
kidney is not responding appropriately and further indicates
that renal phosphate wasting is contributing, in part or in total,
to the hypophosphatemia.
As I have already discussed, in addition to dietary phosphate
intake, parathyroid hormone is the other important regulator of
urinary phosphate excretion. Inappropriate urinary phosphate
excretion therefore implies either increased secretion of para-
thyroid hormone or a defect in the normal tubular transport of
phosphate (Table 2). Elevations of parathyroid hormone in turn
reflect either a primary abnormality of parathyroid secretion
(primary hyperparathyroidism) or increased secretion due to a
disturbance in calcium homeostasis that lowers the serum
calcium, such as intestinal malabsorption or disturbances in
vitamin D metabolism. Urinary phosphate wasting in the ab-
sence of increased levels of PTH can be an isolated defect, can
exist in association with idiopathic hypercalciuria, or can be
part of a generalized defect in proximal tubular function (Fan-
coni syndrome) that is associated with varying combinations of
glucosuria, aminoaciduria, uricosuria, and bicarbonate wasting.
The isolated defect variably referred to as phosphate diabetes,
familial hypophosphatemic rickets, or vitamin D-resistant rick-
ets can be manifested as a familial X-linked syndrome or as an
acquired form of vitamin D-refractory osteomalacia, which
often is associated with mesenchymal tumors.
The patient under discussion today manifested renal phos-
phate wasting in the presence of normal parathyroid hormone
levels. There was no evidence of a disturbance in renal tubular
transport of glucose, amino acids, or uric acid, and she had no
family history of bone disease. Removal of a vascular tumor
was associated with immediate correction of the phosphate
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Fig. 3. Conceptual model of phosphate transport in the proximal
convoluted tubule. The essential elements include Na-Pi cotransport at
the brush border membrane and phosphate diffusion at the antiluminal
membrane. The energy for phosphate entry is provided by the sodium
concentration gradient. (From Ref. 2; © S. Karger AG, Basel.)
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Table 2. Renal phosphate wasting syndromes
Primary hyperparathyroidism
Vitamin D defiency with secondary hyperparathyroidism
Lack of calciferol
Diet
Malabsorption
Inadequate sunlight
Lack of 25-hydroxycholecalciferol
Liver disease
Phenobarbital, phenytoin
Nephrotic syndrome
Lack of l,25(OH)2D3
Vitamin D-dependent rickets
Phosphate transport defect
Isolated: Vitamin D-resistant rickets
Familial
Adult sporadic (with or without glycinuria)
Idiopathic hypercalciuria
Tumor associated (oncogenic osteomalacia)
Generalized: Fanconi syndrome
transport abnormality and she therefore represents an example
of tumor-induced, or oncogenic, osteomalacia.
Pat ho genesis of vitamin D-resistant rickets
Renal phosphate wasting and disordered bone formation
characterize the familial disorder of X-linked hypophosphate-
mic rickets [26]. Because of the similarities between the clinical
presentation of this disease and vitamin D deficiency, and
because of the condition's resistance to physiologic replace-
ment doses of vitamin D, the disorder also has been termed
vitamin D-resistant rickets. Its cause has been difficult to
define, and investigation has focused on two hypotheses. The
first hypothesis posits a primary abnormality in vitamin D
metabolism that results in decreased intestinal absorption of
calcium and phosphate; secondary hyperparathyroidism in turn
produces renal phosphate wasting, hypophosphatemia, and
skeletal abnormalities. The second hypothesis postulates that
the primary defect resides in the renal tubule itself and leads to
deficient reabsorption of phosphate; hypophosphatemia is per-
ceived as the cause of the skeletal abnormalities. Although most
investigators agree that the kidney plays the primary role in the
phosphate wasting, the exact nature of the defect and the role of
vitamin D metabolites in the pathogenesis of the defect remain
unclear. I would like to summarize some of the recent progress
in this area, although unfortunately it is not yet possible to tie all
of the new data together into a neat package.
Secondary hyperparathyroidism versus intrinsic renal tubu-
lar defect. Three lines of evidence argue against diminished gut
calcium transport and consequent secondary hyperpara-
thyroidism as the underlying cause of vitamin D-resistant
rickets. Earlier studies, which had suggested that calcium
infusion could decrease phosphate excretion in patients with
this disease, implied that parathyroid hormone played a patho-
genetic role [27]. It now is clear that PTH levels are normal in
untreated patients [28—301 but that phosphate transport does
respond to manipulation of PTH secretion. Second, treatment
with large doses of vitamin D or its metabolites does not alter
the phosphate transport defect despite a markedly positive
calcium balance and normal levels of PTH [31]. Probably the
most convincing data, however, have come from studies of an
animal model. The Hyp Y mouse developed by Eicher and
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Fig. 4. Phosphate transport rate in the proximal tubule and distal
nephron in normal mice (solid circles) and hypophosphatemic litter-
mates (mutants, open circles) before and after thy roparat hyroidectomy
(TPTX). Note reduced transport rate in the intact mutant mice com-
pared to controls. With TPTX, transport rate increases but remains
reduced in mutants compared to controls. (Reproduced from The
Journal of Clinical Investigation, 1979, 63:1203, by copyright permis-
sion of The American Society for Clinical Investigation [33].)
colleagues exhibits X-linked familial hypophosphatemia, renal
phosphate wasting, and rickets, and is presumed to be a
relevant animal model of the disease in humans [32]. Micro-
puncture studies demonstrated decreased proximal tubular
phosphate reabsorption [33]. Most important, although phos-
phate reabsorption increased following parathyroidectomy, the
rate of transport remained low compared to that in controls
(Fig. 4). This transport rate was not increased to the levels
observed in controls despite infusion of phosphate and an
increase in filtered load (Fig. 5). Decreased phosphate uptake
has been localized to the brush-border membrane in vesicle
studies of membranes from affected mice [34].
Defective vitamin D metabolism. Despite evidence that sec-
ondary hyperparathyroidism is not the proximate cause of the
renal phosphate wasting in vitamin D-resistant rickets, evi-
dence is emerging that a defect in vitamin D metabolism plays a
role in some disease manifestations. Although levels of
l,25(OH)2D3 are normal in affected humans [28] and mice [35],
the normal levels are inappropriately low for the prevailing level
of serum phosphate, because hypophosphatemia produced by
phosphate depletion is normally a potent stimulus to
1 ,25(OH)D3 production. This phenomenon has been demon-
strated in control mice in which phosphate restriction signifi-
cantly increased 1 ,25(OH)2D3 levels, whereas I ,25(OH)2D3
decreased below normal in Hyp Y affected mice [35]. In a
separate study, direct measurements of 25(OH)D3-la hydroxy-
lase activity in mouse kidney revealed that phosphate depletion
of normal mice sufficient to achieve serum phosphate levels
comparable to those in the affected mice resulted in a fourfold
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Fig. 5. Effects of phosphate infusion on transport rate in nephron of
TPTX hypophosphatemic mice. Note that despite increase in filtered
load to levels comparable to control TPTX mice (solid circles), the
transport rate remains reduced in hypophosphatemic mutants (open
circles) in proximal tubule and distal nephron. Thus, defective phos-
phate transport persists in the mice despite the absence of P'l' H.
(Reproduced from The Journal of Clinical Investigation, 1979, 63:1203,
by copyright permission of The American Society for Clinical Investiga-
tion [33].)
greater increase in 25(OH)D3-la hydroxylase activity than that
in affected mice [36]. Finally, as illustrated in Figure 6, Lyles
and Drezner showed that intravenous administration of PTH, a
potent stimulator of 25(OH)D3-la hydroxylase activity in nor-
mal humans, produced a much smaller increment in
1,25(OH)2D3 concentration in patients with X-linked hypophos-
phatemic rickets despite equivalent increases in urinary cAMP
excretion [37].
Sporadic, adult-onset vitamin D-resistant rickets and tumor-
induced osteomalacia. Sporadic, nonfamilial, vitamin D-resist-
ant rickets first appearing in adulthood was initially described
by McCance in 1947 [38]. Over the next 25 years, approximate-
ly 20 patients were characterized by Dent and Stamp [39].
Clinical features included bone pain, muscle weakness, and loss
of height due to vertebral collapse. Radiologically and bio-
chemically, these patients' disease appeared identical to the
sex-linked form, with the additional feature in some of in-
creased urinary glycine excretion. In 1970, Salassa, Jowsey,
and Arnaud called attention to the syndrome of recovery from
adult-onset hypophosphatemic osteomalacia after removal of
benign soft-tissue tumors [40], The authors reported 2 patients
and reviewed 4 others from the literature. It is interesting that
one of those 4 was McCance's original patient who completely
recovered from phosphate wasting coincident with the removal
of a tumor of the femur [41]. Since 1970 approximately 40 more
patients with tumor-induced osteomalacia have been reported
[42—48]. In many of these, the tumors were found because they
were close to the surface, large, or because they invaded
skeleta' structures. One can speculate that small, clinically
inapparent tumors hidden in extraskeletal connective tissue
may go undetected in some patients currently thought to have
sporadic vitamin D-resistant rickets. The patient discussed
today, for example, underwent extensive evaluation for a tumor
when she was originally hospitalized, but none was found.
Because many of these lesions are vascular, there is consider-
able promise that blood-pool scans will prove a sensitive tool
for detecting clinically silent tumors.
In addition to the defect in phosphate excretion, these
patients usually manifest low plasma levels of 1 ,25(OH)2D3
120
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Fig. 6. Effects of PTH on serum 1,25(OH)2D3 levels in normal subjects
and patients with X-linked hypophosphatemia (XLH). Note that the
levels increased significantly in both groups but were significantly
greater in normals than in patients. (Reproduced from Ref. 37.)
despite decreases in serum phosphate and normal levels of
25(OH)D3 and PTH [43—45]. I should emphasize that decreased
levels of 1,25(OH)2D3 in these patients, in contrast to the
"inappropriately" normal levels in the patients with familial
disease, might serve as a marker for the presence of a tumor.
Although most of the patients in the original reports had
neoplasms of mesenchymal origin, often giant cell vascular
tumors, the syndrome recently was described in patients with
prostate carcinoma, with breast carcinoma, and with the epider-
ma! nevus syndrome [44—46]. Remission of the syndrome with
removal of the tumor obviously suggests a humoral origin, but
direct demonstration of this pathogenetic mechanism is lacking.
Three studies have suggested evidence of phosphaturic activity
in saline extracts of such tumors [46—48]. More recently, Lyles
et al transplanted tumor tissue from an affected patient with
prostatic cancer into athymic nude mice [49]. The tumor-
bearing mice developed phosphate wasting, hypophosphate-
mia, and defective 25(OH)D3-la hydroxylase activity.
Relationship between abnormal phosphate transport and
abnormal vitamin D metabolism. The concurrence of similar
metabolic defects in phosphate transport and vitamin D metab-
olism in X-linked hypophosphatemic rickets in humans and in
the mouse model, as well as in tumor-induced osteomalacia in
humans, clearly suggests a relationship between these defects.
Although not as well characterized, paradoxically normal levels
of 1 ,25(OH)2D3 in the presence of hypophosphatemia also have
been observed in the Fanconi syndrome [50]. Further, the
similarity between sites of tubular phosphate transport and sites
Oncogenic hypophosphatemic osteomalacia 119
lmpd Ca
balance
Fig. 7. Model of the pathophysiology of vitamin D-resistant rickets.
Components of the model are speculative (see text).
of 1 ,25(OH)2D3 production suggests that a single cellular defect
might explain the abnormalities in phosphate transport and in
vitamin D metabolism. A simple defect reducing phosphate
traffic through the cell cannot adequately explain these observa-
tions, because increased levels of 1 ,25(OH)2D3 are found in
patients with phosphate depletion, parathyroid hormone ex-
cess, and idiopathic hypercalciuria with phosphate wasting [51].
On the other hand, diminished 1 ,25(OH)2D3 production cannot
explain the phosphate transport defect, because 1 ,25(OH)2D3
levels are not low in the familial forms despite the presence of
the defect; physiologic replacement doses of vitamin D or its
metabolites do not correct the transport defect 1521, and the
effects of chronic administration of 1 ,25(OH)2D3 on phosphate
transport are, if anything, inhibitory rather than stimulatory
[19]. We currently can only speculate that an alteration in the
intracellular milieu is responsible for defective I ,25(OH)2D3
production and phosphate transport (Fig. 7). The fact that
patients with tumor-induced osteomalacia manifest identical
abnormalities, both of which are transferable by transplanting
tumor tissue, raises the possibility of an unidentified humoral
agent. Again, one can speculate that X-linked hypophosphate-
mic rickets is a genetically transmitted endocrinopathy associ-
ated with autonomous production of this unknown factor, but
none of the studies to date in patients or hypophosphatemic
mice have adequately addressed this possibility. Culture of
proximal tubule cells from affected mice and of the cells'
transport characteristics should provide important new infor-
mation in this regard.
Therapeutic approach
While we remain ignorant of the cellular abnormality respon-
sible for the transport defect, we can reasonably state that the
attendant signs and symptoms are the consequence of disor-
dered mineral metabolism. Phosphate depletion both in humans
and in experimental animals causes osteomalacia despite in-
creased levels of l,25(OH)2D3. One initially might suppose that
treatment should consist of administration of large doses of
phosphate. But phosphate administration reduces intestinal
calcium absorption, lowers serum calcium, and produces sec-
ondary hyperparathyroidism. Increased levels of parathyroid
hormone can aggravate the bone disease both directly and
indirectly by decreasing renal phosphate reabsorption. Given
that 1 ,25(OH)2D3 levels are inappropriately low, and that
vitamin D deficiency produces similar bone lesions, these
patients can reasonably be treated with vitamin D. Although
this therapeutic regimen can raise serum phosphate somewhat,
it is not curative. The increase in serum phosphate following
vitamin D therapy probably reflects a combination of increased
gastrointestinal absorption as well as suppression of PTH levels
and allows increased tubular transport of phosphate. Because
these patients might not be able to adequately convert
25(OH)D3 to l,25(OH)2D3, therapeutic levels of 1,25(OH)2D3
may not be achieved despite large doses of vitamin D2 [311. A
therapeutic regimen therefore must be designed with the follow-
ing goals in mind: to increase serum phosphate (by increasing
gastrointestinal absorption), prevent secondary hyperpara-
thyroidism, suppress PTH if possible, and provide levels of
1,25(OH)2D3 sufficient to promote bone healing. The ideal
therapy probably comprises a combination of l,25(OH)2D3,
calcium, and phosphate. Lyles, Harrelson, and Drezner
showed that although large doses of vitamin D2 in combination
with oral phosphate and calcium improved phosphate balance
and increased serum phosphate and 25(OH)D3 levels, this
regimen actually suppressed l,25(OH)2D3 levels and did not
completely heal the bone lesions [31]. Similarly, physiologic
doses of 1 ,25(OH)2D3 produce some improvement in phosphate
balance but do not heal the bone disease [53]. High-dose
therapy sufficient to produce marked increases in serum
1,25(OH)2D3 does seem to completely heal the bone abnormali-
ties. A combination of 3 g/day of 1 ,25(OH)2D3 and 2 g/day of
oral phosphorus completely healed the histologic abnormalities
154]. With this regimen, serum phosphate and TmP/GFR both
increased to the normal range. Plasma levels of 1 ,25(OH)2D3
increase markedly above normal with this regimen and, al-
though the serum calcium level remains normal, urinary calci-
um excretion increases markedly; presumably this rise reflects
suppression of parathyroid hormone, For complete healing of
bone disease, normal levels of serum phosphate probably are
necessary (Fig. 8). Achieving normal levels of serum phosphate
in the presence of a renal transport defect requires a marked
increase in intestinal phosphate absorption in combination with
suppression of PTH secretion. Patients with vitamin D-resistant
rickets, in addition to having the renal transport defect, do not
respond normally to negative phosphate balance with increased
1,25(OH)2D3 production. The therapeutic regimen therefore
must include phosphate and large doses of l,25(OH)2D3.
Whether the increased levels of 1 ,25(OH)2D3 play a direct role
in improving mineralization in addition to increasing serum
phosphate cannot be determined from the available data and
remains to be investigated.
Questions and answers
DR. NIcoLAos E. MADIAS: You have indicated that removal
of the tumor in patients with tumor-associated vitamin D-
resistant rickets leads to remission of the syndrome, suggesting
the presence of a tumor-generated, humoral, phosphaturic
principle. You also have speculated that the autonomous pro-
duction of such a factor might be responsible for the metabolic
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defects observed in X-linked hypophosphatemic rickets in
humans and in the mouse model. This hypothesis implies that
nothing is inherently wrong with the renal tubule itself. Has this
thesis ever been tested in the mouse model using either micro-
perfusion or transplantation?
DR. AGUS: No, not directly. No studies have utilized in-vitro
perfusion of tubules dissected from the mice and, to my
knowledge, no one has attempted cross-circulation or trans-
plantation experiments. As the defect is apparent in brush-
border membrane vesicles isolated from the kidneys of affected
mice, one could suggest that this is evidence of an intrinsic
defect. Vesicles from animals with acquired metabolic or hor-
monal disturbances of phosphate transport (such as phosphate
depletion or parathyroidectomy) also exhibit alterations in
vitro, however. The argument is therefore not convincing.
DR. JOHN T. HARRINGTON: The phosphate wasting in this
patient with tumor-induced phosphaturia disappeared within 48
hours of removal of the tumor. Assuming that this phenomenon
is due to a humoral factor, one would anticipate that the 1,25-
dihydroxy-vitamin D levels also would return to normal within
48 hours. Has anyone measured 1,25-dihydroxy-vitamin D
levels 1 or 2 days after operation in such patients to determine
whether this hypothesis is correct?
DR. AGUS: Yes, Sweet and coworkers demonstrated a pro-
gressive rise in 1 ,25(OH)2D3 beginning as soon as 24 hours after
removal of a hemangioma in a patient with oncogenic osteoma-
lacia [451.
DR. JEROME P. KASSIRER: What is known at a molecular level
about the factor that instigates the phosphaturia?
DR. Aous: At present we have no direct information of this
type; the evidence for the existence of this factor is circumstan-
tial. Three groups have been able to demonstrate phosphaturia
with saline extracts of the tumor [46—48], and phosphaturia is
transferable with tumor transplantation [49]. Isolation, identifi-
cation, and characterization of the phosphaturic principle have
not been accomplished.
DR. KASSIRER: In comparing vitamin D-resistant rickets of
the familial variety and the variety secondary to tumors, does
one find any distinguishing characteristics other than the disap-
pearance of the syndrome when the inciting tumor is removed?
DR. AGUS: In the familial syndrome, l,25(OH)2D3 levels are
within the normal range, albeit inappropriate for the degree of
hypophosphatemia. In patients with the tumor-associated syn-
drome, these levels are truly low. The l,25(OH)2D3 level
therefore is a very important marker for the presence of a
tumor, at least at the moment; anyone who presents with
sporadic vitamin D-resistant rickets and a low 1 ,25(OH)2D3
level should be presumed to have a tumor until proven other-
wise. As recognition of this marker has taken place only within
the last several years, it would be important to check levels in
these patients who are currently being followed.
DR. HARRINGTON: Do these patients given high doses of 1,25-
dihydroxy-vitamin D—amounts three to four times a physiolog-
ic dose—become hypercalcemic?
DR. Aous: Long-term experience with this regimen is very
limited. Dr. Marc Drezner, who has treated several patients in
this fashion, suggests that hypercalcemia does not become a
problem until the bone lesions are healed. Supraphysiologic
doses of 1 ,25(OH)2D3 can be necessary for as long as a year to
heal bone lesions, and the dosage may have to be decreased
thereafter.
DR. DAVID CAHAN (Chiefof Nephrology, Faulkner Hospital,
Boston): Do all patients who meet the chemical criteria for
having renal phosphate wasting with a low 1,25-vitamin D level
develop rickets? I ask because my practice contains a family
that I have been puzzled over for a few years. The father is 80
years old; the two sons are about 60 years old. Phosphate
wasting, inappropriately low to normal I ,25(OH)2D3 levels, and
normal PTH levels are present, but no evidence of tumor or
radiologic evidence of bone disease has been found so far in any
of the 3 patients.
DR. AGUS: Patients with a familial syndrome characterized
by reduced tubular reabsorption of phosphate, hypophosphate-
mia, and normal levels of PTH without rickets have been
described. These people often have bone alterations, but the
lesions usually are much less severe than are those in the typical
patient with vitamin D-resistant rickets [55]. We have insuffi-
cient information at present to know whether differences exist
in vitamin D metabolism in these patients, or whether they
represent a milder form of the disease.
DR. JERRY MCCAULEY (Division of Nephrology, NEMC): Is
there any evidence that this humoral substance is a
prostaglandin?
DR. AGUS: We have no direct evidence, but administration of
aspirin or indomethacin has no effect on the expression of the
disease. In normal individuals, these drugs also have little effect
on phosphate transport.
DR. ANDREW LEVEY (Division of Nephro/ogy, NEMC): You
mentioned earlier that phosphorus-depleted animals have in-
creased fractional tubular reabsorption of phosphate not attrib-
utable to parathyroid hormone or vitamin D, Have experiments
been performed to examine whether this effect is the result of
alterations in a different humoral substance? For instance, it is
interesting to speculate that under normal circumstances base-
line levels of such a hormone might contribute to phosphate
reabsorption, phosphate depletion might reduce hormone levels
and lead to renal phosphate conservation, and ectopic produc-
tion by a tumor might result in phosphate wasting.
DR. AGUS: The hypothesis is certainly an interesting one but
to date has not proven fruitful. Attempts by Bonjour et alto
transmit the adaptive response in rats with plasma or whole
blood from phosphate-depleted animals have not been success-
ful [56]. In addition, Brazy and coworkers were unable to
demonstrate effects of plasma on phosphate transport in isolat-
ed perfused proximal tubules from phosphate-depleted animals,
Increased GI P04 Oral P04
absorption administration
Normal serum PG4
1,25(OH)2D
I Decreased PTH
secretion
lncreasedTm for P04
Ito low normal range)
Healing of
—
— — — — rntnera!;zatio
Fig. 8. Therapeutic approach to vitamin D-resistant rickets.
Oncogenic hypophosphatemic osteomalacia 121
whereas perfused tubules from phosphate-depleted animals
exhibited increased transport despite perfusion for more than
an hour with fluids derived from normal animals [57].
DR. LEVEY: Does this syndrome produce alterations in other
vitamin D metabolites, such as 24,25-dihydroxy-vitamin D3?
DR. AGUS: I am not aware of direct measurements of 24,25-
dihydroxy-vitamin D3 in patients with familial vitamin D-
resistant rickets. Many factors including phosphate seem to
influence 1-alpha hydroxylation and 24-hydroxylation of
25(OH)D3 in a reciprocal fashion. I would not be surprised
therefore to find elevated levels of 24,25(OH)2D3 in this syn-
drome. In one patient with oncogenic osteomalacia,
24,25(OH)2D3 levels were found to be normal at the same time
that low levels of 1,25(OH)2D3 were documented [45].
DR. KASSIRER: Coe asserts that the primary disorder in
idiopathic hypercalciuria is a primary renal calcium leak [63,
64]. You listed idiopathic hypercalciuria as a disorder of phos-
phate transport. What is the evidence for disordered phosphate
metabolism, and do you have a hypothesis that links it to
hypercalciuria?
DR. AGUS: In an early description of the syndrome of
idiopathic hypercalciuria, Aibright and colleagues pointed out
the association with hypophosphatemia [58]. The issue has been
controversial since that time, and frank hypophosphatemia
(serum phosphate less than 2.5 mgldl) generally is considered to
be distinctly unusual. On the other hand, the mean serum
phosphate in these patients usually is lower than the mean value
in a group of normocalciuric patients [51, 59, 60]. In addition,
when urine phosphate is factored for serum phosphate and
filtered load of phosphate (TmPO4/GFR), most investigators
find reduced reabsorption, evidence for a tubular defect in
phosphate transport. In addition to a defect in tubular phos-
phate transport, which persists after reduction of PTH with
calcium infusion [51], we and others have found evidence for a
defect in proximal tubule sodium transport in these patients [51,
61]. Increased levels of 1,25(OH)2D3 also have been described,
and most investigators concur that PTH levels are rarely
increased in patients with idiopathic hypercalciuria [51, 61—63].
The original suggestion of a primary renal calcium leak causing
negative calcium balance and secondary hyperparathyroidism
thus no longer seems tenable. Experimental phosphate deple-
tion produces increased levels of 1,25(OH)2D3, increased gut
calcium absorption, increased bone resorption, and a defect in
renal tubular calcium transport [1]. We and others have suggest-
ed that these tubular abnormalities and alterations in phosphate
metabolism could produce the hypercalciuria in these patients.
This could occur in several ways. Increases in levels of
I ,25(OH)2D3 due to either altered proximal tubular function or
hypophosphatemia could lead to increased gut absorption and
bone resorption. This change would be expressed clinically as
either diet-dependent calciuria, fasting calciuria on a low-
calcium diet, or both. Each of these situations would present as
hypercalciuria without elevated levels of PTH. In fact, most
patients with idiopathic hypercalciuria probably exhibit ele-
ments of both hyperabsorption and fasting calciuria with nega-
tive calcium balance on a low-calcium diet. In addition, the
unusual patient with calciuria and elevated PTH levels would be
explained by renal calcium loss due to either a primary tubular
defect or direct effects of hypophosphatemia on renal tubular
calcium transport.
DR. KASSIRER: I believe Coe acknowledges that the PTH
levels are normal, but he still believes that the renal leak is
primary in almost all cases.
DR. AGUS: I think the issue is partly a semantic one. As
originally defined, diagnosis of a renal leak required the pres-
ence of elevated levels of PTH [64]. The definition currently is
being broadened so that it no longer requires increased PTH but
includes patients with negative calcium balance, that is, those
with urinary calcium excretion that exceeds calcium intake [63].
This situation could occur with increased bone resorption as
well as with a primary renal calcium leak. The increased
excretion could be due to suppressed PTH, effects of phosphate
depletion on calcium transport, increased levels of
1,25(OH)2D3, or a defect in transport of sodium, calcium, or
both. I think both Dr. Coe and I agree that the separation of
patients with idiopathic hypercalciuria into renal and absorptive
subgroups is no longer useful [63] and that definition of the role
and mechanism of disordered phosphate metabolism and ele-
vated levels of l,25(OH)2D3 deserves careful attention.
DR. MADIAS: Do micropuncture studies demonstrate a defect
in proximal tubular sodium reabsorption, in addition to de-
creased phosphate reabsorption, in the mouse model of vitamin
D-resistant rickets?
DR. Aous: In the 2 reported studies, no defect in sodium
transport was identified. But it is possible that a subtle defect
escaped detection.
DR. HARRINGTON: In normal individuals who are phosphate
restricted and in whom urinary phosphate excretion is essential-
ly zero, what kinds of stimuli increase the urinary phosphate
excretion? I am interested in knowing the relative strength of
the factors that regulate renal tubular phosphate reabsorption.
DR Aous: Several factors have been shown to increase
phosphate excretion and restore responsiveness to PTH in
phosphate-depleted animals. These include ammonium chlo-
ride-induced acidosis [65, 66], administration of nicotinamide
[13], and chronic administration of l,25(OH)2D3 in TPTX rats
[19]. In addition, recent studies have shown that glucocorti-
coids and glucagon also can increase phosphate excretion in
phosphate-depleted animals [67, 68]. Whether these various
factors act independently or through a common pathway such
as gluconeogenesis is obviously receiving intense interest.
DR. MICHAEL MADAI0 (Division of Nephro!ogy, NEMC): I
noticed that you posit phenytoin-induced osteomalacia as a
defect in 25-hydroxy-vitamin D. As you know, it has been
shown that 1 ,25(OH)2D3 levels are normal in these patients
[69]. Is this another cause of vitamin D-resistant rickets? If so,
could this agent be a probe to the study of the mechanism of the
defect induced?
DR. Acus: Despite reductions in 25(OH)D3, l,25(OH)2D3
levels are not low in anticonvulsant-induced osteomalacia [69].
In another series, 1,25-dihydroxy-vitamin D3 levels are not low
despite reductions in 24,25(OH)2D3 [70]. Anticonvulsants can
directly inhibit vitamin D-stimulated active intestinal calcium
transport [71], and they also can impair both PTH-mediated and
non-PTH-mediated bone resorption [72]. The mechanism of the
hypocalcemia and osteomalacia therefore is probably multifac-
torial. But anticonvulsant-induced abnormalities are, for the
most part, reversed by modest although pharmacologic doses of
vitamin D [73]; in that sense this entity differs significantly from
vitamin D-resistant rickets.
DR. MADIAS: Has calcitonin been implicated in the pathogen-
esis of this syndrome?
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DR. AGUS: Calcitonin levels in this patient and in others with
oncogenic osteomalacia have been normal [74]. Brunette and
colleagues reported marked increases in calcitonin-sensitive
adenylate cyclase activity in nephron segments of hypophos-
phatemic mice [75]. The physiologic significance of this obser-
vation has not been explained, however.
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